Furthermore, IL-27 has the potential to interact with novel therapeutics; it synergizes with poly(I:C), a TLR3 agonist, to reduce proliferation of melanoma and prostate cancer cells via TRAIL or TLR3, respectively (76, 77). Here, IL27 is linked to prostate carcinoma.